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The interleukin-10 gene-deﬁcient (Il10
−/−) mouse is a model of human inﬂammatory bowel disease and Ppara has been identiﬁed
asoneofthekeygenesinvolvedinregulationofcolitisinthebacteriallyinoculatedIl10
−/− model.Theaimswereto(1)characterize
colitis onset and progression using a histopathological, transcriptomic, and proteomic approach and (2) investigate links between
PPARα and IL10 using gene network analysis. Bacterial inoculation resulted in severe colitis in Il10
−/− mice from 10 to 12 weeks
of age. Innate and adaptive immune responses showed diﬀerences in gene expression relating to colitis severity. Actin cytoskeleton
dynamics, innate immunity, and apoptosis-linked gene and protein expression data suggested a delayed remodeling process in
12-week-old Il10
−/− mice. Gene expression changes in 12-week-old Il10
−/− mice were related to PPARα signaling likely to control
colitis, but how PPARα activation might regulate intestinal IL10 production remains to be determined.
1.Introduction
The interleukin-10 gene-deﬁcient (Il10
−/−) mouse is a well-
established model of human inﬂammatory bowel disease
(IBD)andusedtostudythecomplexhost-environment(e.g.,
diet, bacteria) interactions and the action of potential ther-
apeutics [1]. Il10
−/− mice develop a Crohn’s disease (CD)-
like colitis when exposed to commensal bacteria, whereas
no colitis is observed in the wildtype and germ-free Il10
−/−
mice,whichsuggestsanimportantroleforIL10incontroling
tolerance towards commensal bacteria and in preventing
colitis in these mice [2, 3]. IL10 signals through Janus kinase
1/signal transducer and activator of transcription 3 and
p38 mitogen-activated protein kinase-dependent pathways
to induce suppressor of cytokine signaling-mediated [4]o r
heme oxygenase 1-dependent [5] anti-inﬂammatory mecha-
nisms. The immunopathology in Il10
−/−mice represents a T-
helper cell type 1 (Th1)- and Th17-polarized inﬂammation
with high colonic expression of interferon gamma (IFNγ)a s
the main Th1-derived pro-inﬂammatory cytokine and IL17
[6, 7].
Both the severity and time-course of colitis in Il10
−/−
mice are inﬂuenced by the inbred strain background when
maintained under the same conditions. The colitis in Il10
−/−2 PPAR Research
mice on the C57BL/6J background is mild to moderate
[6], compared with when the Il10
tm1Cgn allele is bred into
the 129/SvEv, C3H/HeJBir, or C3H.SW background strains,
where colitis is severe and progressive [8–10]. This suggests
that other genes or gene interactions particular to the genetic
background of each strain modify the development of colitis.
Intestinal inﬂammation also develops more consistently
when Il10
−/− mice (C57BL/6J background) raised under
conventional conditions are inoculated with a mixture of
pure Enterococcus isolates (E. faecalis and E. faecium) alone,
or combined with conventional intestinal ﬂora derived
from healthy C57BL/6J mice [11]. The timeline of colitis
development is unknown in these bacterially inoculated
Il10
−/− (C57BL/6J) mice.
Studies to date have mostly applied transcriptomic [11–
14]a n dp r o t e o m i c[ 15] methods separately to intestinal
tissue samples of various murine models of experimental
colitis and of IBD patients. It is important to integrate
gene and protein expression data to get a more compre-
hensive understanding of phenotypic changes. A previous
study showed that conventional non-inoculated Il10
−/−
mice (C57BL/6J background) developed increasing colonic
inﬂammation, peaking at 12 weeks of age [16].
The ﬁrst hypothesis of this study was that distinct gene
and protein expression patterns could be deﬁned in non-
inﬂamed (7 weeks of age) and colitic (12 weeks of age)
Il10
−/− mice.Sincethetime-courseofcolitisinthebacterially
inoculated Il10
−/− mouse model (C57BL/6J background)
used by Roy et al. [11] is undeﬁned, the ﬁrst aim was to
characterize colitis onset and progression in this model and
to extend previous studies [11–15] by using a combined
histopathological, transcriptomic, and proteomic approach.
GenenetworkanalysisidentiﬁedthePparageneasoneof
thekeygeneswithdecreasedexpressionlevelsassociatedwith
severe colitis when comparing bacterially inoculated Il10
−/−
and C57 mice [17]. A critical role for PPARα in regulating
inﬂammationwasﬁrstidentiﬁedbyDevchandetal.[18]who
observed a prolonged inﬂammatory response in Ppara
−/−
mice. PPARα-ligands showed anti-inﬂammatory eﬀects in
experimental colitis including the Il10
−/− mouse model [19,
20]. Based on these studies [17–20], the second hypothesis
was that PPARα and IL10 signaling pathways are interlinked
during colitis. The secondary aim was to investigate the
involvement of PPARα regulation in Il10
−/− mice before and
after colitis onset using gene network analysis.
2.Methods and Materials
2.1. Animals and Induction of Colitis. A total of 30
male Il10
−/− (C57BL/6J background, formal designation
B6.129P2-Il10<tm1Cgn>/J) and 30 male C57 control
(C57BL/6J) mice were obtained from The Jackson Labo-
ratory (Bar Harbor, Maine, USA). For convenience and
consistencyinreporting,theiragewasdeﬁnedas35daysor5
weeks of age at the start of the study. Mice were individually
housed in standard shoebox size cages containing untreated
wood shavings (Hi Tech Security Disposals Ltd., Auckland,
New Zealand) and maintained under conventional condi-
tionswithatemperatureofapproximately22◦C,50%relative
humidity, and a 12-hour light-dark cycle.
After 4 days, all mice were inoculated orally with a
mixture of pure E. faecalis and E. faecium strains and
complex intestinal ﬂora derived from healthy C57BL/6J
mice raised under conventional conditions to obtain a
moreconsistentandreproducibleintestinalinﬂammation,as
described previously [11].
2.2. Experimental Design. The objective of this experiment
was to study the onset and progression of colitis and asso-
ciated changes in gene and protein expression in bacterially
inoculated Il10
−/− mice as a model for future nutrigenomics
studies to explore the eﬀects of nutrition on IBD pathophys-
iology. Mice were randomly assigned to 5 sampling groups
(7, 8.5, 10, 12, and 14 weeks of age). The mice had free
access to water and were fed an AIN-76A standard powder
diet prepared in-house. The diet composition has been
described previously [11]. Throughout the experimental
period, dietary intake was estimated daily by weighing
uneaten food and adjusted to equal the mean amount of
food consumed by the Il10
−/− mice on the previous day. All
mice were weighed thrice a week and carefully monitored for
disease symptoms (weight loss, soft feces, inactivity).
Tissue sampling was performed at 7, 8.5, 10, 12, and 14
weeks of age. Mice were euthanized by CO2 asphyxiation
and cervical dislocation, and cardiac puncture was then
performed. There was a fast-feed period prior to sampling as
described previously [17], and the intestine was isolated and
cut open lengthwise. One piece of each intact intestinal sec-
tion (duodenum, jejunum, ileum, and colon) was stored at
roomtemperaturein10%phosphate-buﬀeredformaldehyde
for histopathological assessment; another was immediately
frozen in liquid nitrogen and kept at −80◦Cf o rg e n ea n d
protein proﬁling.
2.3. Histology. The histopathological assessment of the full
thickness intestinal sections (duodenum, jejunum, ileum
or colon) and the scoring method have been described
previously [17]. This method produces a histological injury
score (HIS) for each sample. It is the sum (total HIS) of
principal histological aspects (inﬂammatory cell inﬁltration,
tissue destruction, and tissue repair). A total HIS score
of each intestinal section from 0–3 was regarded as no
inﬂammation, from 4–6 as moderate inﬂammation and ≥7
as severe inﬂammation.
2.4. RNA Isolation, Microarray Hybridization, and Analysis.
RNA isolation and microarray hybridization have been
described previously [17]. The microarray experiment used
15 arrays based on the histopathological assessment of the
colon: three colon samples of Il10
−/− mice at 7 weeks of age
(nocolitis),fourofIl10
−/− miceat12weeksofage(moderate
colitis), four of C57 mice at 7 weeks of age (no colitis),
and four of C57 mice at 12 weeks of age (no colitis). At 7
weeks of age, one Il10
−/− mouse died of unknown causes
andtwootherswerealreadyshowingmoderatesignsofcolon
inﬂammation and were thus excluded. Each individual RNAPPAR Research 3
sample was hybridized with a reference sample onto the
array. Array data were submitted to the Gene Expression
Omnibus, accession number GSE17990.
Statistical analysis and quality assessment of the microar-
ray data were performed using linear models for microarray
analysis (limma) within the Bioconductor framework as
described previously [17]. All arrays passed the quality
control and were included in the analyses. Intensity ratios
for all microarray spots were normalized using a local
linear regression analysis (LOESS) to remove the eﬀect of
systematic variation in the microarrays and no background
correctionwasnecessaryduetohomogeneoushybridization.
The normalized array data of each time point were log2-
transformed and averaged. For each comparison of interest
(Il10
−/− versus C57 mice 7 weeks and Il10
−/− versus C57
mice 12 weeks), a list of diﬀerentially expressed genes was
generated.
2.5. Quantitative RT-PCR. Quantitative RT-PCR (qRT-
PCR) has been described previously [17]. Ten genes (ATP-
binding cassette subfamily B member 1, Abcb1A;a l d e -
hyde dehydrogenase 1 family member A1, Aldh1A1;c a r -
boxylesterase 2, Ces2; fatty acid binding protein 2, Fabp2;
insulin-like growth factor binding protein 5, Igfbp5; inter-
leukin 1 beta, Il1B; matrix metallopeptidase 13, Mmp13;
Ppara, sterol regulatory element binding protein 1, Srebf1
and sulfotransferase family 1A phenol-preferring member
1, Sult1A1) were used for quantiﬁcation and microarray
veriﬁcation. Genes were selected to include both signiﬁcantly
and non-signiﬁcantly regulated genes pertaining to pathways
aﬀected by inﬂammation, for example, those related to
detoxiﬁcation, transport, immunity, or metabolism. The
primer sequences for target and reference genes are available
upon request. The mRNA expression of all genes reported
was normalized to calnexin (Canx) gene expression.
2.6. Protein Isolation, LC-MS Analysis of Peptides, MS/MS
Data Processing, and Analysis. The protein-containing lower
layer of the same TRIzol processed sample from which
RNA was derived was used for protein isolation and fur-
ther identiﬁcation by liquid chromatography and tandem
mass spectrometry (LC-MS/MS). The protein pellets stored
in 0.3M guadinine hydrochloride in 95% ethanol were
processed according to manufacturer’s instructions (TRIzol
protocol, Invitrogen) through two washes and a ﬁnal ethanol
wash, and then allowed to air-dry. Resolubilization buﬀer
(7M urea (BioRad), 2M thiourea (Sigma), 4% CHAPS
(BioRad), 40mM Tris (Invitrogen)) was added and samples
incubated at 22◦C, 600rpm, overnight in a Thermomixer
(Eppendorf). After centrifugation, supernatants were used
to determine protein concentration using the Bradford
protein assay with bovine serum albumin as a standard [21].
Volumes of samples that required pooling were calculated to
produce total aliquots of 50μg per treatment. Gels were run
as duplicate biological replicates using the same samples as
described for the microarray design. The 50μg total protein
oftreatmentandcontrolsampleswerelabeledwith200pmol
of cyanine-2 and cyanine-5 dyes (GE Healthcare, Uppsala,
Sweden), respectively, as described by the manufacturer. The
labeled treatment and control sample were combined to
make 100μg protein and run on Immobiline Drystrips (GE
Healthcare, 18cm, pH 3–11 nonlinear) in an equal volume
of 7M urea, 2M thiourea, 4% CHAPS, a few grains of
Bromophenol Blue (Sigma), 2% pH 3–11 NL IPG buﬀer
(GEHealthcare),and65mMDTTbuﬀer(Sigma)toseparate
the proteins in the ﬁrst dimension. The ﬁrst dimension,
equilibration, and second dimension were performed as
previously described [22]. Precision Plus protein standard
p l u g s( B i o R a d )w e r eu s e da sm o l e c u l a rw e i g h tm a r k e r s .
Immediately after electrophoresis, the gels were washed
in double-distilled H2O and visualized using a Typhoon
(TM) 9400 imager (GE Healthcare). The cyanine-2 images
were scanned using a 488nm laser and a 520nm band
pass 40 emission ﬁlter, whereas the cyanine-5 images were
scanned using a 633nm laser and a 670nm band pass 30
emission ﬁlter. All gels were scanned at a resolution of
200μm, and analyzed using Phoretix 2D Evolution software
(Nonlinear Dynamics). Staining was performed by placing
gels into modiﬁed Neuhoﬀ colloidal Coomassie stain (17%
ammonium sulphate, 3% phosphoric acid, 34% methanol,
0.1% Coomassie G-250) [23], after which gels were dried
o ng l a s sp l a t e sa tr o o mt e m p e r a t u r eu n d e rc e l l o p h a n ea n d
stored.
Diﬀerentially expressed proteins were only ﬂagged as
signiﬁcant where the fold abundance for each biological
replicate changed in the same direction and either both gave
a value either <−1.5- or >1.5- fold, or where one biological
replicategaveavalue<−2-or>2-foldandtheotherbiological
replicate gavea value<−1.3 or>1.3. Signiﬁcant protein spots
were excised from the dried gels, rehydrated in deionized
water, and digested with trypsin. Brieﬂy, 25mM ammonium
bicarbonate in 50% acetonitrile was added to the gel pieces
which were then incubated in a Thermomixer (1400rpm,
22◦C, 10 minutes) with up to two repeats of this step,
depending on the density of the original staining. The gel
pieces were then dried in a vacuum centrifuge (Speedyvac)
and rehydrated at room temperature in a trypsin/HCl mix
(20μL trypsin of a stock made from 25μgv i a lo fR o c h e
modiﬁed trypsin (sequencing grade) in 50μL 1 mM HCl
(BDH), 200μLN H 4HCO3 (Sigma) pH 8.0, 10μL 100%
acetonitrile (BDH)). Following overnight incubation in the
Thermomixer (37◦C, 600rpm), 30μLo f5 %f o r m i ca c i d
(Pierce) in 50% acetonitrile (Sigma) was added to the gel
pieces which were sonicated for 5 minutes. The samples
were brieﬂy centrifuged and the supernatent removed which
was repeated twice. Two additional extractions in formic
acid/acetonitrile were repeated and pooled. Recovered pep-
tides were concentrated by reducing the ﬁnal volume of
the extracts to approximately 10μL in a vacuum centrifuge,
followed by resuspension to a volume of 20μLw i t hf o r m i c
acid/acetonitrile.Thepeptidesolutionswerestoredat −20◦C
until MS was performed.
Tryptic peptides were separated and analyzed using
an Ettan multidimensional liquid chromatography system
(GE Healthcare) coupled to an LTQ linear ion trap mass
spectrometer with a nanospray ionisation interface (Ther-
moQuest, Finnigan, San Jose, CA, USA). Samples (2μL)4 PPAR Research
Table 1: Body weight and dietary intake of Il10
−/− and C57 mice at 7, 8.5, 10, 12, and 14 weeks of age.
Weeks of age
Body weight (g) Dietary intake (g)
C57 mice Il10
−/− mice C57 mice Il10
−/− mice
7 18.8 ± 0.4 18.2 ± 0.8 3.4 ± 0.1 3.3 ± 0.2
8.5 20.3 ± 0.9 19.0 ± 0.3 3.6 ± 0.1 3.9 ± 0.3
10 22.5 ± 0.6 19.9 ± 0.4∗ 3.7 ± 0.0 3.9 ± 0.1
12 24.8 ± 0.7 21.0 ± 0.8∗ 3.6 ± 0.1 3.5 ± 0.2
14 25.3 ± 0.4 19.8 ± 0.7∗ 3.6 ± 0.1 3.5 ± 0.3
Data shown as mean ± standard error of mean (SEM) per group of mice sacriﬁced. Body weight was measured thrice weekly and dietary intake was estimated
and adjusted daily to equal the mean amount of food consumed by Il10−/− mice on the previous day to ensure similar intakes between C57 and Il10−/− mice.
∗P < 0.05 comparing Il10−/− versus C57 mice of the same age.
were injected onto a 300μmI D× 5m mt r a pc o l u m n
(Zorbax 300-SB C18) for in-line desalting and separated on
a nanoscale reverse phase chromatography column 75μm
ID × 150mm, 3μm (LC Packings, San Francisco, CA, USA)
in high-throughput conﬁguration at 280nL/minute with a
linear gradient from 0 to 60% B over 50 minutes (A: 0.1%
formic acid; B: 84% acetonitrile and 0.1% formic acid). Data
were acquired using a top 3 experiment in data-dependent
mode with dynamic exclusion enabled.
MS/MS data were analyzed using TurboSEQUEST pro-
tein identiﬁcation software [24, 25] and spectra were
searched against the NCBI (National Center for Biotech-
nology Information) Mus musculus database. Modiﬁcations
were set to allow for the detection of oxidized methionine
(+16) and carboxyamidomethylated cysteine (+57). The
criteria used for a positive peptide identiﬁcation for a doubly
charged peptide were a correlation factor (XCorr) >2.0,
a delta cross-correlation factor (dCn) >0.1 (indicating a
signiﬁcant diﬀerence between the best match reported and
the next best match), and a high preliminary scoring (Sp).
For triply charged peptides the correlation factor threshold
was set at 2.5. All matched peptides were conﬁrmed by visual
examination of the spectra.
2.7. Bioinformatics Analysis of Pathways and Functions.
IPA (Version 7.0, Ingenuity Systems Inc., Redwood City,
CA, USA) was used for pathway, network, and functional
analyses of diﬀerentially expressed probes in the microarray
dataset as described previously [17] and of diﬀerentially
expressed proteins. EASE (software version 2.0, National
Institutes of Health, USA) was used to identify enriched
biological themes within gene lists using GO category over-
representation analysis [26]. A stringent set of gene probes
diﬀerentially expressed according to the microarray analysis
were uploaded into EASE along with a list of all genes on
the microarray to test for over-representation of annotation
classes. An EASE score (adjusted Fisher’s exact test for
statistical signiﬁcance) was calculated for likelihood of over-
representation of hierarchical categories based on biological
processes, molecular functions, and cellular components
using the GO public database. Gene categories with an EASE
score <0.05 and an FDR or q<0.05 were considered to
be signiﬁcantly over-represented. The data ﬁles containing
gene and protein identiﬁers (gene and protein accession
number) and the corresponding changes in expression levels
were uploaded into the IPA program. Genes and proteins
from the dataset that satisﬁed the cut-oﬀ criteria of FC ≥
1.5 (up- or down-regulated), FDR or q<0.05, and FC
≥ 1.5, respectively, were considered for analyses. Pathways
were considered to be aﬀected by the development of colon
inﬂammation when the probability value calculated by the
Fisher’s exact test was <0.01 and where at least 20% of the
genes from a particular pathway were diﬀerentially expressed
in the microarray dataset.
2.8. Statistical Analysis. All statistical analyses (body weight,
dietary intake, HIS, and qRT-PCR data) were performed
using ANOVA in GenStat (10th edition, VSN International,
Hemel Hempstead, UK), on log-transformed data where
necessary in cases of unequal variances. A probability value
of less than 0.05 was considered as signiﬁcant while a
probability value greater than 0.05 but lower than 0.10 was
considered a trend.
3. Results
3.1. Animal Body Weight and Dietary Intake. There was no
diﬀerence between Il10
−/− and C57 mice in terms of average
body weight at the beginning of the experiment (16.5 ±
0.3 versus 16.9 ± 0.2g, Table 1). During the course of the
experiment, Il10
−/− mice gained weight more slowly (with
a loss in body weight observed between 12, and 14 weeks of
age) than C57 mice, resulting in a lower average body weight
at 7, 8.5, 10, 12, and 14 weeks of age when compared to
the C57 mice. This was signiﬁcant (P<0.05) at 10, 12, and
14 weeks of age. Dietary intake was not diﬀerent between
Il10
−/− andC57miceatanytimepointinthestudy(Table 1).
3.2. Development and Characterization of Intestinal Inﬂam-
mation. Histological analysis showed that the average total
HIS in Il10
−/− mice was highest in the colon, and only two
mice displayed moderate inﬂammation in the ileum. No
signs of inﬂammation were observed in the duodenum or
jejunum of Il10
−/− mice or in any of the diﬀerent intestinal
sectionsofC57mice(Figure 1).Therefore,statisticalanalysis
wasperformedonthecolontissueofIl10
−/− mice.Therewas
a signiﬁcant diﬀerence in the average total HIS in the colon
between Il10
−/− and C57 mice at 8.5, 10, 12 and 14 weeks ofPPAR Research 5
Table 2: Time of onset and incidence of colon inﬂammation in
Il10
−/− mice.
Weeks of age 7 8.5 10 12 14
Number of mice sampled
Il10
−/− mice (total 281) 56665
C 5 7 m i c e ( t o t a l 3 0 ) 66666
Number of mice with inﬂamed
colon2
Il10
−/− m i c e 24664
C 5 7 m i c e 00000
Incidence of colon inﬂammation (%)
Il10
−/− mice 40 67 100 100 80
C 5 7 m i c e 00000
1Two Il10−/− mice died during the study due to unknown causes. 2Mice
were regarded as inﬂamed when their total colon histological injury score
(HIS) was >3 (4–6 moderate inﬂammation, ≥7 severe inﬂammation). All
C57 mice had a total colon HIS ≤ 3.
age.TwoIl10
−/− miceat7weeksofageshowedinitialsignsof
colon inﬂammation, but not the other three mice (Table 2).
Most Il10
−/− mice developed moderate colitis already by 8.5
weeks of age. It became apparent that the average total colon
HIS of Il10
−/− mice increased over time peaking between 10
and 12 weeks of age, and a decrease between 12 and 14 weeks
of age.
Colitis was mainly characterized by inﬂammatory cell
inﬁltration (monocytes and neutrophils) but also featured
tissue destruction (crypt loss and oedema) and tissue repair
(hyperplasia). The colon of Il10
−/− mice was highly inﬂamed
by 10 weeks of age and showed moderate inﬂammation
by 12 and 14 weeks of age (Figure 1). The total colon
HIS in 10-week-old Il10
−/− mice was signiﬁcantly higher
(P<0.05) and a trend was observed at 12 weeks of age
(P = 0.07) compared to 7-week-old Il10
−/− mice. There
was also less variability in the individual colon HIS at 8.5,
10, and 12 weeks compared to 7 and 14 weeks of age. The
inﬂammatory lesions were transmural involving most layers
of the intestinal wall. There was thickening of the mucosal
layerandformationofcryptabscesseswithlossofgobletcells
(Figure 2).
3.3. Inﬂammation-Induced Changes in Expression Proﬁles.
Seven and 12 weeks of age were chosen to assess changes
in colon gene and protein expression because these two
time points represented no inﬂammation (7 weeks of age)
in most of the mice (two mice with signs of inﬂammation
were excluded) and moderate inﬂammation (12 weeks of
age) in Il10
−/− mice. Pathway and network analysis using
IPA was conducted on the transcriptome and proteome
data. The transcriptome data were also subjected to GO
analysis using EASE to conﬁrm and further support the IPA
analysis. As expected, at the gene level, more changes were
observed at 12 weeks than at 7 weeks of age in Il10
−/− mice
compared to C57 mice of the same age, with genes mostly
being up-regulated at each time point in the colon of Il10
−/−
mice. Those gene changes are illustrated in Figure 3 which
shows the genes over-represented in the EASE analysis when
comparing Il10
−/− and C57 mice at 7 and 12 weeks of age.
The mean expression of selected genes obtained by qRT-PCR
mostly conﬁrmed the changes in expression levels from the
microarray analysis.The changesin expression levels ofCes2,
Il1B, Igfbp5, and Srebf1 genes became signiﬁcant in the colon
of 7-week-old and 12-week-old Il10
−/− mice, respectively by
using the more sensitive qRT-PCR analysis (Table 3).
Only four consistent protein expression changes were
identiﬁed at 7 weeks of age in a direct comparison of Il10
−/−
versus C57 mice across the pooled biological replicates (pool
1 and pool 2), with two decreased and two increased in
expression levels. Of these, only two met the threshold
criteria and were visible after staining for spot picking and
subsequent identiﬁcation. At 12 weeks of age, 44 consistent
protein expression changes were observed in Il10
−/− versus
C57 mice across the pooled biological replicates (pool 1 and
pool 2) with 22 decreased and 22 increased in expression
levels. Here, 42 protein expression changes met the threshold
criteria and were selected for subsequent identiﬁcation. The
combined 44 spot-features identiﬁed over the two time
points represented 40 unique proteins (excluding multiple
isoforms due to post-translational modiﬁcations) and are
shown in the gel image depicted in Figure 4, and listed in
Table 4. In seven cases, two or more proteins or protein
isoforms were identiﬁed in the same 2D gel spot-feature.
Several of these biological functions and metabolic and
signaling pathways have previously been shown to be gov-
erned by PPARα after ligand-induced activation, including
fatty acid-, lipid and amino acid metabolism, cell cycle,
immune response, and cell death both in the small intestine
[27]a n dc o l o n[ 17].
3.4. Gene Ontology, Network/Function, and Pathway Analysis
of Colonic Genes and Proteins of Il10
−/− and C57 Mice at 7
Weeks of Age. Genes diﬀerentially expressed at 7 weeks in
the colon of Il10
−/− compared to C57 mice were classiﬁed
into 1493 GO categories. Only 21 of these categories were
over-represented based on an EASE score <0.05 and q<
0.05; these are listed in Table 5. The EASE analysis of
gene expression indicated that several biological processes
were over-represented such as antigen presentation, carbo-
hydrate, and lipid metabolism for energy utilization and
steroid metabolism. Over-represented functional categories
included MHC class II receptor activity. Most of the colonic
genesintheseGOcategoriesshowedup-regulatedexpression
in Il10
−/− compared to C57 mice at 7 weeks of age.
In IPA, 50 networks were generated from the genes
diﬀerentially expressed in the colon of Il10
−/− mice relative
to C57 mice at 7 weeks of age. The themes of the ﬁve
highest scoring networks (P<0.05 using Fisher’s exact
test)whichencompassedthehighestnumberofdiﬀerentially
expressed genes in the transcriptome dataset were cancer,
cell cycle, growth, proliferation, and death and cell-mediated
immune response (Table 6). As there were only two proteins
(adenylate cyclase-associated protein 1 and glutamate dehy-
drogenase 1) that had lower abundance, and one protein
(peroxiredoxin) with higher abundance between Il10
−/− and6 PPAR Research
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Figure 1: Total histological injury score for duodenum, jejunum, ileum, and colon sections of Il10
−/− and C57 mice at 7, 8.5, 10, 12, and 14
weeks of age. The individual scores and the average score (—) of each sampling group are shown. Statistical analysis was performed only for
total colon HIS of Il10
−/− mice and diﬀerent letters mean that total colon HIS diﬀers compared to 7-week-old Il10
−/− mice (a, b, P<0.05
and c, 0.05 <P<0.1).
C57 mice (both at 7 weeks of age), no network analysis was
carried out for protein in IPA.
The most signiﬁcantly regulated pathways in IPA con-
taining most of the diﬀerentially expressed genes (20%)
included antigen presentation (MHC class II genes such
as Hla-Dm, Hla-Dq,a n dHla-Dr members) and interferon
signaling pathway for which the expression levels of genes
were mostly increased (Table 7).
3.5. Gene Ontology, Network/Function, and Pathway Analysis
of Colonic Genes and Proteins of Il10
−/−and C57 Mice at
12 Weeks of Age. At 12 weeks, diﬀerentially expressed genes
were classiﬁed into 1570 GO categories and 32 of these
categories were signiﬁcantly over-represented with an EASE
score <0.05 and q<0.05 and are listed in Table 8.
Genesinbiologicalprocesscategoriesassociatedwithdefense
response to biotic (e.g., pathogen) stimulus or stress were
the most over-represented among the up-regulated genes,
followed by humoral and innate immune response and anti-
gen presentation. Genes assigned to protein activation, such
as post-translational changes targeting membrane proteins,
were also over-represented, and were mostly up-regulated in
Il10
−/−compared to C57 mice.
In IPA, 48 networks were generated from the colonic
genes diﬀerentially expressed in Il10
−/−compared to C57
mice at 12 weeks of age. In Table 6, the top 3 biological func-
tions for the most signiﬁcant transcriptomic and proteomic
networks are shown. These transcriptomic and proteomicPPAR Research 7
(a) (b) (c)
Figure 2:Hematoxylin-eosin-stainedcolonsectionsofIl10
−/− andC57mice.(a)Colonsection(×20)fromanon-inﬂamedC57mouseat12
weeksofage.(b)Colonsection(×100)fromanIl10
−/− mouseat7weeksofagewithnoinﬂammation.(c)Moderatetosevereinﬂamedcolon
section (×40) from an Il10
−/− mouse at 12 weeks of age. Lesions involve most of the colon section with mainly monocyte and neutrophil
inﬁltration (←), crypt abscesses, and loss of crypt and goblet cells ().
Table 3: Validation of gene expression results from microarray analysis using qRT-PCR.
Gene symbol
Fold change microarray Fold change qRT-PCR Canx
Il10
−/− versus C57
7w e e k s
Il10
−/− versus C57
12 weeks
Il10
−/− versus C57
7w e e k s
Il10
−/− versus C57
12 weeks
Abcb1A −3.4 −2.8 −5.2 −4.9
Aldh1A1 −1.5
∗ −3.0 −1.5# −3.4
Ces2 −1.8
∗ −3.1 −2.9 −5.6
Fabp2 −1.9 −5.6 −1.5# −9.8
Igfbp5 −1.5
∗ 1.6
∗ −1.9# 2.8
Il1B 1.8
∗ 6.43 .48 .5
Mmp13 1.0
∗ 1.82 .7# 9.9
Ppara −2.0 −1.7 −5.6 −3.8
Srebf1 1.0
∗ 1.0
∗ 1.2# 1.8
Sult1A1 −3.2 −3.1 −3.6 −3.3
Canx (calnexin)referencegeneusedtotonormalizethedata; ∗microarrayresultwasnotsigniﬁcantlydiﬀerentusingmoderatedt-statisticsandfalsediscovery
rate (FDR) control in limma; genes that satisﬁed the criterion of FC ≥ 1.5 and q<0.05 were considered to be signiﬁcantly diﬀerent; #qRT-PCR result was not
signiﬁcantly diﬀerent using ANOVA.
networks share the following biological functions: cell-
mediated immune response is represented in transcriptome
4 and proteome 1, cancer is represented in transcriptome
2 and proteome 3, and cell-to-cell signaling and interac-
tion is represented in transcriptome 1 and 4. Thus, the
theme linking transcriptomic and proteomic networks is
cell migration and changes in tissue structure (implications
for actin cytoskeleton dynamics) as well as cell death with
associated inter- and intracellular signaling and initiation of
the immune response.
The most signiﬁcantly regulated pathways in IPA fea-
turing most of the diﬀerentially expressed genes (20–
40%) included signaling processes (Table 7). The signaling
pathwaysincludedantigenpresentationpathway(MHCclass
I,e.g.,HlamembersandMHCclassII,e.g.,Hla-Dm,Hla-Dq,
Hla-Dr members, genes); graft-versus-host disease signaling
and allograft rejection signaling (e.g., Il1B, Tnfa), interferon
signaling (e.g., Ifng), role of RNA-dependent protein kinase
(PKR) in interferon induction and antiviral response (e.g.,
Bcl), dendritic cell maturation and complement system, and
the genes in those pathways were mostly up-regulated.
4. Discussion
This study characterizes colitis onset and progression at
the histopathological, transcriptome, and proteome level in
bacterially inoculated Il10
−/−mice (C57BL/6J background).
Here, we show that most Il10
−/− mice developed moderate8 PPAR Research
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Figure 3: Genes over-represented in EASE analysis comparing Il10
−/− and C57 mice at 7 or 12 weeks of age. Heat map represents the
expression levels of all diﬀerentially expressed genes in the signiﬁcant GO categories (EASE score <0.05 and q<0.05). The groups are clearly
deﬁned within their clusters and diﬀerences in gene expression are seen for 12-week-old Il10
−/− mice relative to 7-week-old Il10
−/− mice and
12-week-old C57 mice.
colitis already by 8.5 weeks of age and severe colitis peaking
between 10 and 12 weeks of age when compared to 7-week-
old Il10
−/− mice. The nature of colon inﬂammation was sim-
ilar to that displayed by conventionally housed Il10
−/− mice
on the same genetic background not subjected to bacterial
inoculation and represented features characteristic of human
CD [16]. Several aspects of innate and adaptive immune
responses were aﬀected at the gene expression level before
(7 weeks of age) and after (12 weeks of age) colitis onset
in Il10
−/− mice. These ﬁndings agree with the inﬂammatory
and immune responses observed in CD patients who have a
defective interaction between their innate mucosal immune
system and luminal bacteria [28]. This study focuses on
those pathways linking the gene and protein expression
changes such as cytoskeletal rearrangement, cell migration,
and innate immunity that underlie colitis development inPPAR Research 11
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Figure 4: 2D-DIGE gel representing diﬀerentially expressed proteins identiﬁed in the colon tissue of Il10
−/− mice compared to C57 mice at
7 and 12 weeks of age, respectively. Protein annotations are shown in Table 4. The approximate isoelectric point (pI) and molecular weight
(MW) in kDa are given on the x-a n dy-axes, respectively.
Table 5: Categories of genes with expression increase of 2-fold or more in Il10
−/− mice compared to C57 mice at 7 weeks of age using EASE.
System Gene category EASE score FDR
GO Cellular Component spindle cell 3.91E-04 <0.001
GO Molecular Function MHC class II receptor activity 1.25E-03 <0.001
GO Biological Process antigen processing, exogenous antigen via MHC class II 1.37E-03 <0.001
GO Biological Process antigen presentation, exogenous antigen 1.37E-03 <0.001
GO Biological Process alcohol metabolism 2.27E-03 <0.001
GO Biological Process glucose metabolism 4.37E-03 <0.001
GO Biological Process main pathways of carbohydrate metabolism 6.39E-03 <0.001
GO Biological Process protein targeting 7.76E-03 <0.001
GO Biological Process steroid biosynthesis 1.02E-02 <0.001
GO Biological Process steroid metabolism 1.09E-02 <0.001
GO Biological Process sterol biosynthesis 1.29E-02 <0.001
GO Cellular Component microtubule cytoskeleton 1.75E-02 <0.001
GO Biological Process sterol metabolism 1.82E-02 <0.001
GO Biological Process carbohydrate metabolism 1.89E-02 <0.001
GO Biological Process hexose metabolism 1.92E-02 <0.001
GO Molecular Function oxidoreductase activity, acting on CH-OH group of donors 1.96E-02 <0.001
GO Biological Process energy derivation by oxidation of organic compounds 2.47E-02 <0.001
GO Biological Process catabolism 2.54E-02 <0.001
GO Cellular Component soluble fraction 2.82E-02 <0.001
GO Molecular Function oxidoreductase activity, acting on the CH-OH group of donors, NAD or
NADP as acceptor 2.92E-02 <0.001
GO Biological Process monosaccharide metabolism 3.13E-02 <0.00112 PPAR Research
Table 6: Proteome and transcriptome network analysis for expression proﬁles from the colon of 7- and 12-week-old Il10
−/− mice compared
to C57 mice using IPA.
Network Top functional categories
Il10
−/− versus C57 mice at 7 weeks of age
Transcriptome 1 Cancer, Dermatological disease and conditions, Endocrine system development and function
Transcriptome 2 Cardiovascular system development and function, Cancer, Tissue development
Transcriptome 3 Cancer, Cell death, Reproductive system disease
Transcriptome 4 Cell cycle, Cell-mediated immune response, Cancer
Transcriptome 5 Cellular growth and proliferation, Hematological system development and function, Hematopoiesis
Il10
−/−versus C57 mice at 12 weeks of age
Proteome 1 Tissue morphology, Cellular movement, Cell-mediated immune response
Proteome 2 Cell death, Hematological disease, Immunological disease
Proteome 3 Cancer, Tumour morphology, Cellular development
Proteome 4 Cardiovascular disease, Gene expression, Molecular transport
Transcriptome 1 Antigen presentation, Cell morphology, Cell-to-cell signaling and interaction
Transcriptome 2 Cancer, Gastrointestinal disease, Dermatological diseases and conditions
Transcriptome 3 Lipid metabolism, Small molecule biochemistry, Carbohydrate metabolism
Transcriptome 4 Inﬂammatory disease, Cell-to-cell signaling and interaction, Cell-mediated immune response
The top 3 biological functions for the most signiﬁcant transcriptomic and proteomic networks (representing subsets of focus genes and proteins highly
associated with those functions) are shown.
this Il10
−/− mouse model. Since PPARα has previously been
identiﬁed as a potential key mediator in inﬂammation [17],
the ﬁndings of this study showed that Ppara is involved in
signaling processes before and after colitis onset likely to
control colitis. Further, a potential link between PPARα and
IL10 is suggested.
4.1. Change in Transcriptomic Proﬁle with Colitis. Increased
expression levels of membrane-bound Tlr2 and Tlr9 genes
in the colon of 12-week-old Il10
−/− compared to C57 mice
were consistent with their reported function. Peptidoglycan
andlipoproteins fromthecellwallofcommensalbacteriaare
recognizedbyTLR2[28].Theunderlyingabnormalresponse
between the innate immune system to bacterial structures
is mediated via TLR and other pattern-recognition recep-
tors which then regulate antigen-speciﬁc adaptive immune
responses[29].Dendriticcells,animportantcellularcompo-
nentofthemucosalinnateimmunesystem,sampleintestinal
bacteria through pattern recognition with TLR [30]. The
recognition of bacterial structures by TLR2 can lead to
activation of NFκB-MAPK pathways and interferon regu-
latory factor family members [31]. This activation in turn
induces diﬀerentiation of cells producing pro-inﬂammatory
cytokines, such as IFNγ and IL17, responsible for CD-like
inﬂammation [28]. Increased mRNA abundance of the Tlr9
gene in 7-week and 12-week-old Il10
−/− mice compared to
C57 mice may be associated with signaling events in order
to maintain or reestablish colonic homeostasis, respectively.
Lee et al. [31] reported distinct transcriptional responses
of TLR9 activation through apical and basolateral surface
domains to maintain colonic homeostasis and regulate
tolerance and inﬂammation. Basolateral TLR9 activation of
intestinal epithelial cells leads to NFκB signaling, whereas
apical TLR9 stimulation prevented NFκB activation. These
TLR-dependent innate immune responses seemed to be
important in the Il10
−/− mouse colitis model in order to
adapt to luminal bacteria and their antigens.
The gene network analysis in our previous study linked
genes involved in inﬂammatory and immune response,
tryptophan and xenobiotic metabolism, and antigen pre-
sentation [17]. Several genes of these pathways were also
diﬀerentially expressed mostly in the 12-week-old Il10
−/−
mice. The higher expression levels of MHC class I and class
II genes in the colon of Il10
−/− compared to C57 mice
at 12 weeks were likely to be associated with mounting
antigen-speciﬁc adaptive immune responses to bacterial
invasion. The expression level of Ido1, a gene involved in
tryptophan catabolism, was increased at both 7 and 12 weeks
of age in colitic Il10
−/− mice. High expression level of the
anti-inﬂammatory enzyme IDO was observed in intestinal
biopsies from CD patients [32]. The pro-inﬂammatory
cytokine genes Ifng and Tnfa, known as potent inducers of
INDO protein activity [33], had higher mRNA abundance
only in the inﬂamed colon of 12-week-old Il10
−/− mice.
Elevated levels of IL10 and TGFB have also been found in
CD patients, and it was suggested that this modulated the
immune response and caused activation of B lymphocytes
[32]. The increased expression levels of tryptophan (e.g.,
Ido1) and antigen presentation (e.g., Hla c l a s sI Im e m b e r s )
genes in the 12-week-old Il10
−/− mice might be linked to
the restoration of tolerance towards bacterial antigens. In
7-week-old non-inﬂamed Il10
−/− mice, increased Ido1 gene
expression might also be important in the early response to
commensal bacteria preceding colitis due to the deﬁciency of
the Il10 gene. Increased mRNA abundance of genes involved
in the complement activation, antigen presentation, and B-
cell receptor signaling in 12-week-old Il10
−/− mice is in
agreementwithfunctionalimplicationsofPPARαactivation.PPAR Research 13
Table 7: Diﬀerentially expressed genes in the colon of Il10−/− mice compared to C57 mice at 7 and 12 weeks of age.
Gene symbol Gene name GenBank
accession
Il10
−/− versus C57 Il10
−/− versus C57
7 weeks of age 12 weeks of age
FC FDR FC FDR
Actg2 actin, gamma 2, smooth muscle, enteric NM 007392 −1.3 0.315 −1.60 . 0 2
Arhgap12 Rho GTPase activating protein 12 NM 029277 −1.1 0.549 −1.5 <0.001
Arhgdib Rho GDP dissociation inhibitor (GDI) beta NM 007486 1.1 0.562 2.0 <0.001
Arhgef10L Rho guanine nucleotide exchange factor (GEF)
10-like AK028648 2.4 <0.001 2.3 <0.001
Bcl2A1 BCL2-related protein A1 NM 007534 1.6 0.001 2.7 <0.001
Bcl3 B-cell CLL/lymphoma 3 NM 033601 1.6 0.044 1.7 0.015
C1Qa complement component 1, q subcomponent, A
chain NM 007572 1.1 0.67 1.6 0.003
C1Qc complement component 1, q subcomponent, C
chain NM 007574 1.3 0.29 1.8 0.005
C1R complement component 1, r subcomponent NM 023143 1.5 0.018 2.0 <0.001
C1S complement component 1, s subcomponent NM 144938 1.3 0.059 1.9 <0.001
C2 complement component 2 NM 013484 1.2 0.337 2.6 <0.001
C3 complement component 3 NM 009778 1.8 0.015 4.5 <0.001
C4B complement component 4B (Chido blood group) NM 009780 −1.0 0.976 1.6 0.005
Ccl5 chemokine (C-C-motif) ligand 5 (Rantes) NM 013653 1.1 0.7 2.3 <0.001
Cd74 CD74 molecule, major histocompatibility
complex, class II invariant chain NM 010545 4.0 <0.001 5.5 <0.001
Fas Fas (TNF receptor superfamily, member 6) NM 007987 1.9 <0.001 1.5 <0.001
Gsn gelsolin NM 146120 −1.8 0.006 −2.0 <0.001
Hla-A major histocompatibility complex, class I, A NM 010391 1.4 0.201 2.3 <0.001
Hla-B major histocompatibility complex, class I, B NM 008199 −1.4 0.104 1.9 <0.001
Hla-C major histocompatibility complex, class I, C NM 010380 1.4 0.005 2.3 <0.001
Hla-Dma major histocompatibility complex, class II, DM
alpha NM 010386 1.5 <0.001 2.1 <0.001
Hla-Dmb major histocompatibility complex, class II, DM
beta NM 010387 4.9 <0.001 6.6 <0.001
Hla-Dqa1 major histocompatibility complex, class II, DQ
alpha 1 NM 010378 1.8 <0.001 2.9 <0.001
Hla-Dqb2 major histocompatibility complex, class II, DQ
beta 2 NM 010379 3.1 <0.001 5.3 <0.001
Hla-Drb1 major histocompatibility complex, class II, DR
beta 1 NM 010382 2.5 <0.001 4.5 <0.001
Hla-G major histocompatibility complex, class I, G NM 013819 1.4 0.013 2.0 <0.001
Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A
reductase NM 008255 1.7 0.005 1.5 0.005
Ido1(Indo) indoleamine 2,3-dioxygenase 1 NM 008324 6.6 <0.001 8.1 <0.001
Ifng interferon, gamma NM 008337 1.4 0.071 1.7 0.003
Il1B interleukin 1, beta NM 008361 1.8 0.211 6.4 <0.001
Il1Rn interleukin 1 receptor antagonist NM 031167 1.3 0.442 1.8 0.024
Il10 interleukin 10 NM 010548 1.1 0.461 1.1 0.421
Mapk13 mitogen-activated protein kinase 13 NM 011950 1.8 <0.001 1.7 <0.001
Mapk9 mitogen-activated protein kinase 9 NM 016961 1.5 0.004 1.6 <0.001
Nfkbia nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha NM 010907 1.6 0.002 1.6 0.00114 PPAR Research
Table 7: Continued.
Gene symbol Gene name GenBank
accession
Il10
−/− versus C57 Il10
−/− versus C57
7w e e k so fa g e 1 2w e e k so fa g e
FC FDR FC FDR
Nfkbie nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, epsilon NM 008690 1.5 0.001 1.7 <0.001
Ppara peroxisome proliferator-activated receptor alpha NM 011144 −2.0 <0.001 −1.7 0.001
Ppargc1A peroxisome proliferator-activated receptor
gamma, coactivator 1 alpha NM 008904 −1.7 0.008 −1.4 0.052
Tlr2 toll-like receptor 2 NM 011905 1.1 0.857 1.9 0.001
Tlr9 toll-like receptor 9 NM 031178 1.9 <0.001 1.9 <0.001
Tnf tumour necrosis factor (TNF superfamily,
member 2) NM 013693 1.3 0.064 1.7 <0.001
Tnfrsf1B tumour necrosis factor receptor superfamily,
member 1B NM 011610 1.3 0.115 1.5 0.003
Txn thioredoxin NM 011660 −1.2 0.494 −1.0 0.932
Genes were grouped into one or more of the following IPA pathways: antigen presentation, graft versus host disease signaling, allograft rejection signaling,
interferon signaling, role of PKR in interferon induction and antiviral response, dendritic cell maturation, complement system, endoplasmic reticulum stress,
and steroid metabolism. Genes with fold change (FC) ≥1.5 and false discovery rate (FDR) or q<0.05 were considered for pathway analysis.
PPARαhasbeenassociatedwiththeinnateimmuneresponse
of the small intestine using Ppara
−/−and wildtype mice, and
its pharmacological activation inhibited complement activa-
tion,antigenpresentation,andB-cellreceptorsignaling[27].
4.2. Change in Proteomic Proﬁle with Colitis. Proteins diﬀer-
entially expressed in inﬂamed Il10
−/− mice were involved in
cytoskeletalrearrangement,cell-mediatedimmuneresponse,
and pathogen-inﬂuenced signaling. The cytoplasmic actin
gamma 1 and smooth muscle actin gamma 2 proteins
(ACTG1 and ACTG2) were less abundant in the colon
of Il10
−/−compared to C57 mice at 12 weeks of age.
Pro-inﬂammatory cytokines and bacteria can modify tight
junctions interconnecting intestinal epithelial cells via the
actin cytoskeleton so disruption of actin leads to disruption
of tight junctions and loss of barrier function with increased
paracellular permeability [34]. This is further supported by
a study reporting decreased actin-binding gene expression
levels in peripheral blood mononuclear cells of IBD patients
suggesting that disruption of the actin cytoskeleton might
contribute to CD pathogenesis in humans [35]. The ACTG2
protein was also decreased in expression at the gene level
in the 12-week-old Il10
−/− mice compared with C57 mice,
but the Actg2 gene remained unchanged in Il10
−/− mice at 7
weeks of age when the intestinal barrier was presumably still
intact.
Actin-binding proteins including gelsolin (GSN)
involved in the regulation of actin-based motility by
calcium-dependent Rho-family GTPases (e.g., RhoA, Rac1
and Cdc42) were diﬀerentially expressed in the colon
of Il10
−/− mice at 12 weeks of age. Rho-family proteins
share growth-promoting and anti-apoptotic functions,
regulation of gene expression through activation of signaling
molecules, for example, NFκB[ 36]. They can promote actin
cytoskeleton reorganization, but Rho-family proteins diﬀer
in their eﬀect on cell movement; for example, RhoA induces
the formation of stress ﬁbers and focal adhesions [36]. Rho
GDP dissociation inhibitor (GDI) beta (Rho GDIβ) protein,
which is encoded by the Arhgdib gene (mRNA abundance
was increased in 12-week-old Il10
−/− mice), regulates
RhoGTPase activity by inhibiting GDP dissociation to leave
RhoGTPases inactive [37]. This suggests that in the inﬂamed
colon of those Il10
−/− mice, Rho protein activity is being
inhibited by Rho GDIβ and thus inhibits actin cytoskeleton
reorganization. Enhanced T-cell migration as a consequence
of the inﬂammatory state of the intestine is maintained by
pro-inﬂammatory cytokines and has been associated with
increased expression levels of GSN protein in smooth muscle
cells in the small intestine of CD patients [38]. However, the
expression level of GSN protein and Gsn gene was reduced
in the colon of 12-week-old Il10
−/−mice which might reﬂect
a declining inﬂammatory cell movement. This is supported
by the decreased inﬂammatory lesions in the colon of
Il10
−/− mice from 12 weeks to 14 weeks of age and might
be associated with reduced inﬂammatory cell migration.
Gelsolin-null mice have shown reduced neutrophil and
ﬁbroblast movement [39].
The actin cytoskeleton is a ﬂexible system that is built
up or broken down depending on antigen recognition, cell
polarization, and cell adhesion or cell migration. Actin-
binding proteins are involved in surface receptor clustering
during T-cellactivation and migration to dynamic cytoskele-
tal rearrangements at the interface between T-cells and
antigen presenting cells [40]. A study using an in vitro
modelofsimulatedischemia-reperfusionshowedaninvolve-
ment of Rho-kinase-dependent cytoskeletal rearrangement
in apoptosis initiation [41]. In the colon of the 12-week-
old Il10
−/− mice, Rho GDIβ may have inhibited or delayedPPAR Research 15
Table 8: Categories of genes with expression increase of 2-fold or more in Il10
−/−mice compared to C57 mice at 12 weeks of age using EASE.
System Gene category EASE score FDR
GO Biological Process defence response 5.92E-14 <0.001
GO Biological Process response to biotic stimulus 7.39E-14 <0.001
GO Biological Process response to external stimulus 1.38E-12 <0.001
GO Biological Process immune response 4.06E-12 <0.001
GO Biological Process antigen presentation 4.14E-07 <0.001
GO Biological Process antigen processing 4.52E-06 <0.001
GO Molecular Function defence/immunity protein activity 6.14E-06 <0.001
GO Molecular Function MHC class I receptor activity 2.67E-05 <0.001
GO Biological Process response to pest/pathogen/parasite 1.43E-04 <0.001
GO Biological Process physiological process 1.47E-04 <0.001
GO Molecular Function antigen binding 2.31E-04 <0.001
GO Biological Process response to stress 2.49E-04 <0.001
GO Biological Process antigen presentation, endogenous antigen 1.21E-03 <0.001
GO Molecular Function MHC class II receptor activity 1.56E-03 <0.001
GO Biological Process antigen processing, exogenous antigen via MHC
class II 1.67E-03 <0.001
GO Biological Process antigen presentation, exogenous antigen 1.67E-03 <0.001
GO Cellular Component extracellular space 1.75E-03 <0.001
GO Biological Process protein targeting 2.57E-03 <0.001
GO Biological Process humoral immune response 2.97E-03 <0.001
GO Cellular Component plasma membrane 7.23E-03 <0.001
GO Biological Process antigen processing, endogenous antigen via MHC
class I 8.44E-03 <0.001
GO Biological Process response to wounding 1.07E-02 <0.001
GO Molecular Function oxidoreductase activity, acting on CH-OH group
of donors 1.15E-02 <0.001
GO Molecular Function oxidoreductase activity, acting on the CH-OH
group of donors, NAD or NADP as acceptor 1.71E-02 <0.001
GO Molecular Function hydrolase activity 1.86E-02 <0.001
GO Biological Process collagen catabolism 2.07E-02 <0.001
GO Biological Process posttranslational membrane targeting 2.18E-02 <0.001
GO Biological Process innate immune response 2.22E-02 <0.001
GO Cellular Component vesicular fraction 2.51E-02 <0.001
GO Biological Process response to chemical substance 3.06E-02 <0.001
GO Biological Process inﬂammatory response 3.06E-02 <0.001
actin rearrangement, and in part attenuated apoptosis, anti-
apoptosis genes such as Bcl2A1 gene was increased in expres-
sion. BCL3, a component of the cellular cytokine-induced
inﬂammatory signaling cascade, has been shown to interact
cooperatively with PPARGC1α to activate estrogen-related
receptors and PPARα resulting in increased expression of
target genes involved in cellular energy metabolism [42].
Although Bcl3 mRNA abundance was increased, Ppara and
Ppargc1a gene expression levels decreased in 7-week, and 12-
week-old Il10
−/− mice which imply an impaired energetic
adaptation of the colonocytes to bacterial- or cytokine-
induced cellular stress at an early and late stage, respectively.
This is supported by ﬁndings from others that the failure
of regulatory mechanism in Il10
−/− mice under developing
colitis primes the epithelium towards energy deﬁciency and
uncontroled cellular stress leading to tissue damage [15].
IL10 and also PPARα seem to be important in this regulatory
mechanism.
The thioredoxin (TXN) protein, known to function
as an antioxidant in the maintenance of cellular redox
homeostasis, was more highly expressed in 12-week-old
Il10
−/− mice compared with C57 mice. Thioredoxin has
previously been identiﬁed as a PPARα target gene and a
negative autoregulation of PPARα activity by thioredoxin
was suggested as a novel mechanism for controling PPARα
activities and PPARα-related physiological or pathological
processes [43]. The ﬁnding of the present study may also be
explained by a functional down-regulation of normal PPARα16 PPAR Research
activities such as lipid and inﬂammatory regulation through
the thioredoxin-mediated negative autoregulation of PPARα
transcriptional activity.
4.3. Il10
−/− Colitis Model and PPARα Signaling. Several of
the gene expression changes in colitic Il10
−/− mice at 12
weeks of age were related to PPARα signaling. A regulatory
role for PPARα in inﬂammation was ﬁrst shown by the
prolonged duration of inﬂammation in Ppara
−/− mice [18],
and network analysis identiﬁed Ppara as a key mediator gene
decreased in expression during colitis in Il10
−/− compared to
C57 mice [17]. Furthermore, PPARα and also PPARγ ligands
exerted anti-inﬂammatory eﬀects in inﬂammatory disease
models. For example, administration of PPARα (bezaﬁ-
brate) and PPARγ (troglitazone) ligands reduced dextran
sulphate sodium-induced colitis and cell proliferation in
colonic mucosa [19], PPARα ligand fenoﬁbrate decreased
expression levels of pro-inﬂammatory Ifng and Il17 genes
in Il10
−/− mice [20], PPARγ ligand rosiglitazone delayed
colitis onset in Il10
−/− mice [7], and fenoﬁbrate prevented
the progression of autoimmune myocarditis in rats through
increased cardiac Il10 mRNA levels [44].
PPARα is expressed in colonic immune and epithelial
cells where it acts in an anti-inﬂammatory manner upon
activation by a PPARα ligand [20]. In the present study, the
expression level of the Ppara gene was decreased in inﬂamed
and non-inﬂamed colons of Il10
−/− mice when compared
to C57 mice without exogenous ligand-mediated PPARα
a c t i v a t i o n .I ti sk n o w nt h a tP P A R α governs inﬂammation
mainly by down-regulating gene expression such as acute
phase response genes [45]. PPARα (mRNA and protein)
expression levels were decreased in colorectal cancer in
the APCMin/+ mouse model of familial adenomatous poly-
posis compared with matched non-malignant tissue [46].
Ppara
−/− mice show enhanced susceptibility dinitroben-
zene sulfonate (DNBS)-induced colitis [47]. PPARα ligands
reduce colitis in chemically induced and genetic (including
Il10
−/− m i c e )m o d e l so fc o l i t i s[ 19, 20], whereas the absence
of PPARα abolishes the protective eﬀect of the PPARα ligand
WY14643 in DNBS-induced colitis [47]. Thus, activation of
PPARα appears to be a target for controling colitis including
inthisinoculatedIl10
−/− mousemodel.ThedecreasedPpara
gene expression level in 7-week-old Il10
−/− mice suggests
thatimmunecellsmighthavebeenactivatedduetoincreased
bacterial invasion and a lack of regulatory mechanisms
through Il10 gene deﬁciency, even though histopathological
signs of colitis were not clearly evident yet. It has been
reported that PPARα expression in murine lymphocytes is
rapidlydecreasedfollowingT-cellactivationsuggestingarole
for PPARα in immune cells [48].
The anti-inﬂammatory eﬀect of fenoﬁbrate by delaying
colitis onset and progression in Il10
−/− mice indicates that
IL10 is not required in PPARα signaling [20]. In contrast,
another study emphasized the stimulation of the IL10 path-
way in rats treated with fenoﬁbrate to suppress myocarditis
[44]. This implicates a potential PPARα-dependent regula-
tion of IL10. So far, it has been shown that rosiglitazone
induced IL10 production from human mature dendritic cells
and CD4+ T-cells [49]. This eﬀect was PPARγ-dependent
due to a functional PPAR response element for PPARγ in the
human IL10 promoter region.
In conclusion, the ﬁndings from this study identiﬁed
distinct colonic gene and protein expression proﬁles for 7-
and 12-week-old Il10
−/− mice. Gene and protein expression
data linked actin cytoskeleton dynamics, innate immunity,
and apoptosis and suggested a delayed remodeling process in
thecoliticIl10
−/− mice.PPARαmightbeoneofthekeymedi-
atorsinthesesignalingprocessesbeforeandaftercolitisonset
inIl10
−/− mice.Ligand-mediatedPPARαactivationandIL10
production may be important for the anti-inﬂammatory
eﬀects of PPARα observed in inﬂammatory disease models
and possibly in the resolution of inﬂammatory disease in
humans. Conﬁrmation of a role for PPARα activation in
intestinal IL10 production, and clariﬁcation of the mecha-
nism by which this occurs, warrants further investigation.
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